Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Buy
58
DERM Quote, Financials, Valuation and Earnings
Last price:
$5.58
Seasonality move
:
23.1%
Day range:
$5.30 - $5.76
52-week range:
$2.85 - $6.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.98x
P/B ratio:
10.99x
Volume:
59.8K
Avg. volume:
52.1K
1-year change:
51.72%
Market cap:
$120.1M
Revenue:
$79.2M
EPS (TTM):
-$0.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DERM
Journey Medical
|
$14.2M | -- | -4.5% | -- | $10.00 |
|
FBIO
Fortress Biotech
|
$16.3M | -$0.75 | -9.13% | -41.51% | $15.33 |
|
NBY
NovaBay Pharmaceuticals
|
$2.5M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
PTN
Palatin Technologies
|
-- | -$0.42 | -100% | -67.93% | $7.00 |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DERM
Journey Medical
|
$5.75 | $10.00 | $120.1M | -- | $0.00 | 0% | 1.98x |
|
FBIO
Fortress Biotech
|
$1.72 | $15.33 | $47.5M | -- | $0.00 | 0% | 0.34x |
|
NBY
NovaBay Pharmaceuticals
|
$0.60 | $0.85 | $2.9M | -- | $0.00 | 0% | 0.06x |
|
OGEN
Oragenics
|
$0.25 | $1.00 | $3.1M | -- | $0.00 | 0% | 1.00x |
|
PTN
Palatin Technologies
|
$0.80 | $7.00 | $20.9M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.17 | $6.00 | $3.3M | -- | $0.00 | 0% | 1.59x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DERM
Journey Medical
|
64.42% | 1.772 | 16.89% | 0.99x |
|
FBIO
Fortress Biotech
|
71.75% | 0.988 | 900.37% | 0.99x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.646 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | 3.509 | -- | -- |
|
PTN
Palatin Technologies
|
-- | -1.737 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -2.868 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DERM
Journey Medical
|
$9.3M | -$2.9M | -64.68% | -125.77% | -11.16% | -$1.2M |
|
FBIO
Fortress Biotech
|
$9.3M | -$22.1M | -94.06% | -- | -166.72% | -$20.1M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
OGEN
Oragenics
|
-- | -$2.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
-- | -$5.1M | -- | -- | -2356.3% | -$4.8M |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
Journey Medical vs. Competitors
-
Which has Higher Returns DERM or FBIO?
Fortress Biotech has a net margin of -16.34% compared to Journey Medical's net margin of -87.96%. Journey Medical's return on equity of -125.77% beat Fortress Biotech's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical63.87% -$0.12 $30.7M FBIOFortress Biotech63.87% -$0.76 $41M -
What do Analysts Say About DERM or FBIO?
Journey Medical has a consensus price target of $10.00, signalling upside risk potential of 73.91%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 791.47%. Given that Fortress Biotech has higher upside potential than Journey Medical, analysts believe Fortress Biotech is more attractive than Journey Medical.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 FBIOFortress Biotech1 0 0 -
Is DERM or FBIO More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.750, suggesting its more volatile than the S&P 500 by 74.992%.
-
Which is a Better Dividend Stock DERM or FBIO?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Fortress Biotech pays out -14.46% of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or FBIO?
Journey Medical quarterly revenues are $14.6M, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Journey Medical's net income of -$2.4M is higher than Fortress Biotech's net income of -$12.9M. Notably, Journey Medical's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 1.98x versus 0.34x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical1.98x -- $14.6M -$2.4M FBIOFortress Biotech0.34x -- $14.6M -$12.9M
-
Which has Higher Returns DERM or NBY?
NovaBay Pharmaceuticals has a net margin of -16.34% compared to Journey Medical's net margin of -49.65%. Journey Medical's return on equity of -125.77% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical63.87% -$0.12 $30.7M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About DERM or NBY?
Journey Medical has a consensus price target of $10.00, signalling upside risk potential of 73.91%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.08%. Given that Journey Medical has higher upside potential than NovaBay Pharmaceuticals, analysts believe Journey Medical is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is DERM or NBY More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.
-
Which is a Better Dividend Stock DERM or NBY?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or NBY?
Journey Medical quarterly revenues are $14.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Journey Medical's net income of -$2.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Journey Medical's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 1.98x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical1.98x -- $14.6M -$2.4M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns DERM or OGEN?
Oragenics has a net margin of -16.34% compared to Journey Medical's net margin of --. Journey Medical's return on equity of -125.77% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical63.87% -$0.12 $30.7M OGENOragenics-- -$0.38 -- -
What do Analysts Say About DERM or OGEN?
Journey Medical has a consensus price target of $10.00, signalling upside risk potential of 73.91%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 292.77%. Given that Oragenics has higher upside potential than Journey Medical, analysts believe Oragenics is more attractive than Journey Medical.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 OGENOragenics0 1 0 -
Is DERM or OGEN More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.847, suggesting its less volatile than the S&P 500 by 15.305%.
-
Which is a Better Dividend Stock DERM or OGEN?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or OGEN?
Journey Medical quarterly revenues are $14.6M, which are larger than Oragenics quarterly revenues of --. Journey Medical's net income of -$2.4M is higher than Oragenics's net income of -$2.5M. Notably, Journey Medical's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 1.98x versus 1.00x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical1.98x -- $14.6M -$2.4M OGENOragenics1.00x -- -- -$2.5M
-
Which has Higher Returns DERM or PTN?
Palatin Technologies has a net margin of -16.34% compared to Journey Medical's net margin of -2357.27%. Journey Medical's return on equity of -125.77% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical63.87% -$0.12 $30.7M PTNPalatin Technologies-- -$0.12 -$111.5K -
What do Analysts Say About DERM or PTN?
Journey Medical has a consensus price target of $10.00, signalling upside risk potential of 73.91%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 772.06%. Given that Palatin Technologies has higher upside potential than Journey Medical, analysts believe Palatin Technologies is more attractive than Journey Medical.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 PTNPalatin Technologies0 0 0 -
Is DERM or PTN More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.
-
Which is a Better Dividend Stock DERM or PTN?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or PTN?
Journey Medical quarterly revenues are $14.6M, which are larger than Palatin Technologies quarterly revenues of $350K. Journey Medical's net income of -$2.4M is higher than Palatin Technologies's net income of -$2.4M. Notably, Journey Medical's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 1.98x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical1.98x -- $14.6M -$2.4M PTNPalatin Technologies-- -- $350K -$2.4M
-
Which has Higher Returns DERM or TOVX?
Theriva Biologics has a net margin of -16.34% compared to Journey Medical's net margin of --. Journey Medical's return on equity of -125.77% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical63.87% -$0.12 $30.7M TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About DERM or TOVX?
Journey Medical has a consensus price target of $10.00, signalling upside risk potential of 73.91%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 412.82%. Given that Theriva Biologics has higher upside potential than Journey Medical, analysts believe Theriva Biologics is more attractive than Journey Medical.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 TOVXTheriva Biologics0 0 0 -
Is DERM or TOVX More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.
-
Which is a Better Dividend Stock DERM or TOVX?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or TOVX?
Journey Medical quarterly revenues are $14.6M, which are larger than Theriva Biologics quarterly revenues of --. Journey Medical's net income of -$2.4M is higher than Theriva Biologics's net income of -$4.4M. Notably, Journey Medical's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 1.98x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical1.98x -- $14.6M -$2.4M TOVXTheriva Biologics1.59x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Is Alphabet Stock No Longer a Good Bet?
Alphabet tripled its price per share over the past 5…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Sell
50
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
82
EXOD alert for Mar 20
Exodus Movement [EXOD] is up 17.89% over the past day.
Buy
69
SIG alert for Mar 20
Signet Jewelers [SIG] is down 0.64% over the past day.
Sell
36
HQY alert for Mar 20
HealthEquity [HQY] is up 0.28% over the past day.
